Our priority is to preserve the health of people and our planet.
.
- RVP-001: the gadolinium-free general purpose MRI contrast agent.
- All current MRI contrast agents cause accumulation of the heavy metal gadolinium in the brain and body of every patient.
Gadolinium levels in earth's surface waters are rising, impacting aquatic ecosystems and drinking water supplies.
RVP-001, designed to be a direct replacement for current standard of care MRI contrast agents, is based on manganese, a trace element essential for life.
RVP-001 is actively advancing through clinical studies. - Reveal's pipeline: ground-breaking fibrogenesis imaging agents.
- Building on research by Reveal's co-founder, Professor Peter Caravan (Harvard Medical School & Massachusetts General Hospital), Reveal is developing first in class fibrogenesis imaging agents. These agents are designed to identify active fibrotic disease and have potential applications for diagnosis, staging, patient stratification, and monitoring response to treatment in a wide range of fibrotic diseases.
Team
- Vera Hoffman - CEO & Co-Founder
- Vera has led Reveal since its inception and is Principal Investigator of Reveal's SBIR grants from the National Cancer Institute, the National Institute for Diabetes and Digestive and Kidney Diseases, and the National Heart, Lung and Blood Institute. Previously, Vera directed startups and high growth enterprises from idea stage through global scale. She guided the design, development, and commercialization of over a dozen innovative technology-based products; led teams across six continents to identify, plan, and execute new business opportunities for a large global enterprise; and developed the initial business plan for Acquia ($1B exit, 2019). Vera holds degrees in Chemistry and Mathematics, and an MBA from Harvard Business School.
- Peter Caravan - Co-Founder
- Peter is a world leader in MRI contrast agent development and applications. He leads a molecular imaging lab at Massachusetts General Hospital (MGH) focused on contrast agents and molecular probes to image fibrosis and thrombosis, as well as alternatives to GBCAs; Peter is a co-inventor of RVP-001. At MGH he invented two novel molecular tracers and he holds INDs for their ongoing clinical development. In industry Peter was part of the team that developed the FDA-approved blood pool agent Ablavar® (Gadofosveset), and was co-inventor of the thrombus-specific agent EP-2104R, the first molecular MR imaging probe to enter human clinical trials. Peter is a Fellow of the International Society for Magnetic Resonance in Medicine (ISMRM), a Fellow of the World Molecular Imaging Society (MWMIS), and was awarded the 2019 Torsten Almén Award for Pioneering in Contrast Media Research.
- Eric Gale - Co-Founder
- Eric applies chemistry to solve unmet challenges in radiology and biomedical imaging. He is co-inventor of RVP-001 and was instrumental in the discovery of this contrast agent and its preclinical characterization and synthesis. Eric leads a research laboratory at Massachusetts General Hospital focused on developing transition metal complexes as MRI contrast agents, and is a 2023 Blavatnik Therapeutics Challenge awardee. He has a PhD from the University of Georgia and was a NIH-funded Ruth L. Kirschstein National Research Service Award Scholar.
- Susan Stewart - Regulatory Affairs
- Sue is an expert in biopharmaceutical regulatory affairs: devising innovative strategies for novel drugs, overseeing regulatory submissions across all stages of product development, and leading interactions with global health authorities. Sue served in senior regulatory roles at Frequency Therapeutics, Candel Therapeutics, Kaleido Biosciences, Tokai Pharmaceuticals, Transmolecular, Inc, and Genzyme Corporation. Sue has a J.D. and is a Fellow (FRAPS) of the Regulatory Affairs Professionals Society, a Director of the Society’s Board, and holds Regulatory Affairs Certifications (RAC) for both the US and Europe.
- John Amedio - Chemistry, Manufacturing, & Controls
- John is an expert in technical and regulatory CMC development strategy, and has worked with Reveal since the company's first technology transfer. John has delivered profitable and patented pre-clinical through commercial manufacturing processes for drugs including Ablavar®, Arbaclofen, Zinapar™, Zibulin™, Zymafos™, Favipiravir, and multiple NCE’s including peptides and metal-based drugs. John has authored and reviewed CMC sections for numerous regulatory filings (INDs, IMPDs, Amendments, Annual Updates, and NDAs). John earned a PhD in organic chemistry from the University of Delaware.
- Thomas Steele - Nonclinical Pharmacology & Toxicology
- Tom is an expert in pharmacology and toxicology, with extensive experience in preclinical development and toxicology of novel small molecule and biological therapeutics in multiple therapeutic areas. Tom has extensive experience in the drug discovery and development process, as well as regulatory document preparation, review, and submission. He had a vital role in multiple successful “first in human” regulatory applications and served as preclinical expert for two initial marketed product approvals. Tom has held positions at the FDA, large pharmaceutical companies (Roche, Eli Lilly) and small biopharma (Ariad). Tom has a PhD in Pharmacology and Toxicology from Purdue University.
- Philip Graham - Pharmaceutical Development Advisor
- Phil has extensive experience in pharmaceutical product development. He is currently Chief Development Officer at Avilar, and was previously responsible for program development, and product and program management at Concert Pharmaceuticals. Phil has directed the development of over a dozen drugs, including the MRI contrast agents Ablavar® and EP-2104R. Phil has a BS with honors from the University of Otago, New Zealand, and a PhD in Analytical Chemistry from the University of Massachusetts, Amherst.
Reveal's work is supported by three institutes of the National Institutes of Health, Massachusetts agencies, and accelerators. Our investors include a wide range of physicians, patients, and industry players.
